Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertensionheart failure and percutenous coronary interventions (PCI).

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell
 

Feature | Structural Heart | April 22, 2021
The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural...
The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.
News | Hemostasis Management | April 21, 2021
April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market...
Transforming Interventional Cardiology with Structured Reporting using Change Healthcare's cardiovascular information system (CVIS).
Webinar | Cardiovascular Information Systems (CVIS) | April 21, 2021
The adoption of structured reporting within cardiology imaging departments is on the rise. Providers recognize the...
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart | April 21, 2021
As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon "...
News | April 20, 2021
April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the...
The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

The reSept ASD Occluder is the first occluder with a metal-free, bioresorbable frame. It is designed to overcome the limitations of current transcatheter occluders by reducing the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders | April 20, 2021
April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational...
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.

News | Stents | April 14, 2021
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal transseptal crossing devices. This is the only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ own suite of sheaths and with sheaths sold by other manufacturers. 
News | EP Lab | April 14, 2021
April 14, 2021 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal...
The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR).

The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR). The device is an iteration of the successful MitraClip device used for transcatheter mitral valve repairs. 

News | Structural Heart | April 08, 2021
April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for...
A reconstructed vessel segment from a cone-beam CT created table side in the cath lab with the Philips Azurion SmartCT software.

A reconstructed vessel segment from a cone-beam CT created table side in the cath lab with the Philips Azurion SmartCT software. 

News | Angiography | April 07, 2021
April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips...
Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

News | Stroke | April 07, 2021
April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices),...
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

News | Stents | April 06, 2021
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual...
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automated...
Videos | Coronavirus (COVID-19) | April 01, 2021
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
Sponsored Content | Case Study | Cardiovascular Information Systems (CVIS) | April 01, 2021
Washington Health System (WHS) provides healthcare services at more than 40 offsite locations across three counties in...